Here are seven quick facts:
1. In the last few days, Jefferies Group has changed their ratings on a number of healthcare stock.
2. Christopher A. Holden, CEO of AmSurg, sold 3,000 shares of AmSurg stock on the open market in a transaction that occurred Wednesday.
3. The average price for the stock was sold at $69.02, totaling $207,060 for the entire transaction.
4. Shares of AmSurg went down 0.49 percent on Tuesday hitting a low of $68.76.
5. AmSurg has a market cap of $3.28 bullion and a price-to-earnings ratio of 59.38.
6. Analysts anticipate AmSurg will post $3.36 earnings per share for the current fiscal year.
7. Various other analysts have commented on the stock with Goldman Sachs analysts setting a buy rating and $81.00 price target on AmSurg stock.
For more ASC-related news:
Portsmouth Regional ASC files form D for $665k in financing
Dr. Black’s Eyes Associates opening dry eye center — 5 things to know
Dr. Henry Lee joins The Eye Care & Surgery Center in New Jersey
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
